



LUCINE

Press Release

Lucine raises €5.5 million to develop a digital therapy to relieve and treat patients with chronic diseases.

Paris, November 18, 2020

Bordeaux-based startup Lucine raises €5.5 million in funds from Kurma Partners, Bpifrance via its Autonomous Patient Fund, BNP Paribas Développement, Aquiti Gestion and Irdi Soridec to finance the development of its first digital therapy technology to relieve chronic pain. Héméra, a historical shareholder, remains on the board of directors.

Chronic pain affects 25% of the world's population. It can be distinguished from acute pain when it lasts more than three months and is resistant to usual treatments. It is treated in particular with the prescription of opioids whose abuse is responsible for more than 500,000 deaths worldwide according to the World Health Organization. During this period of health crisis, 74% of the French suffered at least one pain during the containment. For 39% of them, these pains had a greater impact on their morale during this exceptional period and only 20% consulted a health professional.¹

Digital Therapies (DTx) provide therapeutic interventions directly to patients using evidence-based, clinically evaluated software to treat, manage and prevent a wide range of diseases and behavioural disorders, mental and physical.

¹ rce : Étude Sanofi, l'AFLAR, l'AFVD - June 2020.

Pioneer in digital care therapies, Lucine develops a mobile application to measure and relieve chronic pain. From the onset of symptoms pain, the patient can, via the application and the facial recognition system, measure the extent of his pain. Based on this measurement, the mobile solution offers personalized therapeutic procedures such as virtual reality and CBT (Cognitive Behavioral Therapy).

This fundraising will allow Lucine to continue the development of scientific and clinical studies using proprietary Artificial Intelligence software that triggers an intervention to relieve persistent suffering, or recurring problems for millions of people.

Maryne Cotty Eslous, Lucine CEO says, "It is a success story for me to be able to demonstrate that it is possible to make innovation in health in France. 100% of this first tour de table is French".



Lucine is a mobile application to measure and relieve chronic pain.

"This method is based on solid scientific fundamentals in products of digital therapy (DTx) that do not induce dependency and risk for patients", underlines Philippe Peltier, Partner at Kurma Partners.

Chahra Louafi, Director, Biotech and Ecotech Investment Division of Bpifrance, said :

"The digital therapy developed by Lucine to relieve patients suffering from chronic pain is an original alternative to conventional drug treatments. We are delighted to support them in their development ambitions".

We are very proud to be part of the Lucine adventure, which combines our two intervention focuses : deeptech and societal impact" adds Camille Le Roux, Investment Director at Aquiti Gestion.

"It is a great honor to support a young entrepreneur who is committed and determined to provide a concrete solution to relieve chronic pain on a long-term. Sophie Pierrin

Lepinard, Investment Director at BNP.

"Lucine is now ideally positioned to shape the future of this new class of drugs," said Benedikt Timmerman, Venture Partner at IRDI SORIDEC.

"We believed in Lucine's vision very early on, supporting her team. Héméra is proud to be at the side of her team for this new stage, to revolutionize the medicine of tomorrow. " Grégory Lefort at Héméra.

A few figures :

- Chronic pain can be distinguished from acute pain when it lasts more than three months and is resistant to usual treatments.
- According to the ANSM in France in its report on the prevention of consumption of opiates (2019), chronic pain represents 12 million French people.
- For an average cost per patient of 1037 per year, and without taking into account the 88 million work stoppages.
- The French Observatory of Drugs and Drug Addiction (OFDT) and the French Observatory of Analgesic Medicines (OFMA), indicate an increase in the consumption of strong opiates over 10 years in France by +120%.

About Lucine :

Lucine, an innovative French company pioneering digital therapies (DTx - Digital Therapeutics), owns two technologies, LUCINE SCALE and LUCINE CARE, and presents a personalized non-drug treatment that meets the primary "evidence based medicine" requirements for regulatory and scientific recognition. Able to perform preclinical, clinical and medical-economic validation studies, Lucine is centered on the patient and their needs.

More informations :

<https://lucine.fr>

<https://twitter.com/lucinegroup>

<https://www.linkedin.com/company/projet-lucine>

Contact : elast@lucine.io – +33 7 85 71 20 21

About Bpifrance and the Autonomous Patient Fund :

Bpifrance's equity investments are made by Bpifrance Investment. Bpifrance finances companies - at every stage of their development in credit, guarantees and equity. Bpifrance supports them in their projects of innovation and on the international scene. Bpifrance now also ensures their export activity to through a wide range of products. Consulting, University, Networking and Program acceleration for start-ups, SMEs and ETIs are also part of the offer offered to contractors. Thanks to Bpifrance and its 50 regional establishments, the entrepreneurs benefit from a close, unique and efficient interlocutor to accompany them to meet their challenges.

Bpifrance's Autonomous Patient Fund, launched at the end of 2017, targets start-ups that develop innovations allowing :

- Optimization of healthcare costs.
- Better care by helping to strengthen the relationship between professional and patient (telemedicine, remote monitoring, digital therapeutics).
- Improved quality and efficiency of care.
- Improvements in the care pathway, particularly for chronic diseases (diabetes, cancers, mental health), by helping to prevent diseases and disorders. complications, facilitating the diagnosis of the disease and monitoring its evolution in real time, thanks in particular to artificial intelligence, the "deep/machine learning".

More information :

www.bpifrance.fr
www.Presse.Bpifrance.fr

Follow us on Twitter : @Bpifrance @BpifrancePresse

Contact : Laure Schlagdenhauffen

laure.schlagdenhauffen@bpifrance.fr - +33 1 41 79 85 38

About Kurma Partners :

Founded in July 2009, Kurma Partners is a Paris-based management company specializing in the financing of innovation in Healthcare and Biotechnology, from pre-creation to development capital.

Kurma Partners, which manages the Kurma Biofund I, II, III, Kurma Diagnostics Fund and Kurma Diagnostics 2, is one of the main players in the financing of therapeutic and medical innovations in Europe, in particular via the following links that it has woven with many prestigious research institutes and hospitals.

More information :

www.kurmapartners.com
Contact : Philippe Peltier

About Aquiti Gestion :

Aquiti Gestion is an AMF-approved management company which actively participates in the financing of start-ups, SMEs and ETIs based in Nouvelle-Aquitaine with a field of full intervention (loan of honor, venture capital, development capital and capital transmission) and multi-sector for investments ranging from 10 k€ to 10 M€.

With more than 500 companies supported, nearly twenty years of existence, about ten funds under management and 3 offices (Limoges, Poitiers, Bordeaux), Aquiti Gestion is a key player in the Neo-Aquitaine ecosystem, which has a strong anchoring regional leader, allowing it to be as close as possible to the entrepreneurs of the Nouvelle-Aquitaine.

Contact : Camille Le Roux Larsabal - camille.leroux@aquiti.fr - +33 6 10 94 84 77

About BNP Paribas Développement :

BNP Paribas Développement, a subsidiary of the BNP Paribas Group, created in 1988, directly invests its equity to support the development of SMEs and ETIs as a minority shareholder. In 2016, BNP Paribas Développement created the WAI Venture Fund in 2016, a structure dedicated to innovation capital that invests in seed and early stage companies.

to support the growth of high-potential start-ups. BNP Paribas développement manages a portfolio of more than 400 companies, including 50 start-ups.

www.bnpparibasdeveloppement.com

About Irdi Soridec Gestion :

Based in Toulouse, Montpellier and Bordeaux, Irdi Soridec Gestion has been investing since 40 years in companies located in the South-West of France at all stages of development (venture capital, development capital and buyout capital). It manages more than 350 M€ through several funds including IRDInov2, a technology seed fund supported by the Fonds National d'Amorçage (FNA), with which it supports Lucine.

<https://www.irdisoridec.fr>

Contact : Agnès Rouvière - agnes@rouvierecommunication.fr

About Héméra :

Founded by entrepreneurs, for entrepreneurs, the accelerator program based in Bordeaux has surrounded itself with experienced entrepreneurial mentors to accompany the growth of startups and invest in them. Héméra is also positioning itself as a key innovation partner for New Aquitaine SMEs working with these nuggets. The Héméra programs and services are operated from iconic coworking locations such as the Héméra Hall and Héméra Ravezies.

Contact : Greg Lefort - greg@hemera.camp